KUKU

KU ScholarWorks

  • myKU
  • Email
  • Enroll & Pay
  • KU Directory
    • Login
    View Item 
    •   KU ScholarWorks
    • Dissertations and Theses
    • Dissertations
    • View Item
    •   KU ScholarWorks
    • Dissertations and Theses
    • Dissertations
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Studies on the mechanisms and consequences of drug-induced perturbations of lysosomal structure and function

    Thumbnail
    View/Open
    Logan_ku_0099D_13112_DATA_1.pdf (2.651Mb)
    Issue Date
    2013-12-31
    Author
    Logan, Randall
    Publisher
    University of Kansas
    Format
    159 pages
    Type
    Dissertation
    Degree Level
    Ph.D.
    Discipline
    Pharmaceutical Chemistry
    Rights
    Copyright held by the author.
    Metadata
    Show full item record
    Abstract
    From a clinical perspective, a drug's pharmacokinetic properties (e.g., the volume of distribution, clearance, and half-life) are vitally important as these parameters are used to establish the proper dosing regimen necessary to achieve a desired drug exposure. Failure to properly account for changes to a drug's expected pharmacokinetic properties, whether perpetrated by pharmacological insult (drug-drug interaction) or a disease state, can result in an improper dosing regimen that either fails to achieve therapeutic drug levels or, conversely, can result in drug levels that reach toxic concentrations. Identifying conditions that can alter the expected pharmacokinetic properties of drugs is therefore immensely important. Previous work in our lab has shown that lysosomotropic drugs, i.e., drugs that preferentially accumulate within lysosomes due to an ion trapping-type mechanism, cause a marked expansion in the volume of lysosomes which can result in a drug-drug interaction involving lysosomes. Although this novel drug-drug interaction was well characterized the mechanistic basis explaining how it developed was not established. Within this work we have explored the cellular mechanisms underlying the development of the drug-induced expansion in lysosomal volume and the ensuing drug-drug interaction. Our data shows that the drug-induced expansion in lysosomal volume is achieved through a combination of reduced vesicle-mediated trafficking out of the lysosomes, the induction of autophagy, and the activation of lysosome biogenesis. We have additionally explored a structure activity relationship which implicates a drug's amphiphilicity and lysosomotropic properties as important features that correlate with their propensity to induce an expansion in lysosomal volume. Overall, the data presented in this work can be used to help explain the sources of variability seen in the pharmacokinetic properties of lysosomotropic drugs. In parallel to these studies we have also explored potential treatment strategies that can reduce the bloated lysosomal volume seen in cells with dysfunctional lysosomes. Using two cell models that exhibit dysfunctional lysosomes (lysosomotropic drug-treated cells or lysosomal storage diseased cells), we have examined how vitamin E helps to recover lysosomal volume. Our data indicates that vitamin E reduces both ion trapping-dependent (aqueous volume of lysosomes) and ion trapping-independent (lipid binding) drug accumulation mechanisms within cells. To our knowledge, this is the first report detailing that vitamin E reduces the aqueous volume of lysosomes. This finding is important as it helps to more fully explain how vitamin E is eliciting its positive effects within cells. Additionally, we have also examined a structure activity relationship of vitamin E and its ability to reduce lysosomal volume. Our data indicates that the physical structure of vitamin E, rather than its antioxidant properties, is the primary feature of vitamin E that correlates with its ability to reduce the bloated lysosomal volume seen in cells with dysfunctional lysosomes. Overall, this data can be used as a foundation to stage additional studies that could ultimately lead to the development of more potent and better drug-like molecules that could be used to treat lysosomal storage diseases and the toxic effects of lysosomotropic drug-treatments.
    URI
    http://hdl.handle.net/1808/21626
    Collections
    • Dissertations [4474]
    • Pharmaceutical Chemistry Dissertations and Theses [141]

    Items in KU ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.


    We want to hear from you! Please share your stories about how Open Access to this item benefits YOU.


    Contact KU ScholarWorks
    785-864-8983
    KU Libraries
    1425 Jayhawk Blvd
    Lawrence, KS 66045
    785-864-8983

    KU Libraries
    1425 Jayhawk Blvd
    Lawrence, KS 66045
    Image Credits
     

     

    Browse

    All of KU ScholarWorksCommunities & CollectionsThis Collection

    My Account

    LoginRegister

    Statistics

    View Usage Statistics

    Contact KU ScholarWorks
    785-864-8983
    KU Libraries
    1425 Jayhawk Blvd
    Lawrence, KS 66045
    785-864-8983

    KU Libraries
    1425 Jayhawk Blvd
    Lawrence, KS 66045
    Image Credits
     

     

    The University of Kansas
      Contact KU ScholarWorks
    Lawrence, KS | Maps
     
    • Academics
    • Admission
    • Alumni
    • Athletics
    • Campuses
    • Giving
    • Jobs

    The University of Kansas prohibits discrimination on the basis of race, color, ethnicity, religion, sex, national origin, age, ancestry, disability, status as a veteran, sexual orientation, marital status, parental status, gender identity, gender expression and genetic information in the University’s programs and activities. The following person has been designated to handle inquiries regarding the non-discrimination policies: Director of the Office of Institutional Opportunity and Access, IOA@ku.edu, 1246 W. Campus Road, Room 153A, Lawrence, KS, 66045, (785)864-6414, 711 TTY.

     Contact KU
    Lawrence, KS | Maps